Idera Pharmaceuticals Inc (IDRA) Expected to Announce Quarterly Sales of $130,000.00
Wall Street analysts forecast that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will post sales of $130,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Idera Pharmaceuticals’ earnings. The highest sales estimate is $150,000.00 and the lowest is $100,000.00. Idera Pharmaceuticals reported sales of $260,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is expected to announce its next quarterly earnings results on Wednesday, May 8th.
On average, analysts expect that Idera Pharmaceuticals will report full-year sales of $490,000.00 for the current year, with estimates ranging from $400,000.00 to $580,000.00. For the next fiscal year, analysts anticipate that the firm will report sales of $6.79 million, with estimates ranging from $420,000.00 to $13.15 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Idera Pharmaceuticals.
Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.06. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.12 million.
NASDAQ:IDRA traded up $0.20 during midday trading on Tuesday, hitting $2.57. 222,948 shares of the company traded hands, compared to its average volume of 328,508. Idera Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $17.12. The firm has a market capitalization of $70.98 million, a PE ratio of -1.13 and a beta of 2.55.
A number of institutional investors have recently made changes to their positions in IDRA. Virtu Financial LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $33,000. Jane Street Group LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $39,000. SG Americas Securities LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $41,000. Squarepoint Ops LLC grew its position in Idera Pharmaceuticals by 45.5% in the 4th quarter. Squarepoint Ops LLC now owns 18,900 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 5,910 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $61,000. 44.71% of the stock is currently owned by institutional investors.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.
See Also: Understanding Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.